EMERYVILLE, Calif.,
Oct. 19, 2023 /PRNewswire/ -- Dynavax
Technologies Corporation (Nasdaq: DVAX), a commercial-stage
biopharmaceutical company developing and commercializing
innovative vaccines, today announced that the Company will present
the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
on Wednesday, October 25 at
1:00 p.m. ET.
The presentation will be webcast and may be accessed through the
"Events & Presentations" page on the "Investors" section of the
Company's website at
https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company
developing and commercializing innovative vaccines to help protect
the world against infectious diseases. The Company has two
commercial products, HEPLISAV-B® vaccine [Hepatitis B
Vaccine (Recombinant), Adjuvanted], which is approved in the U.S.,
the European Union and Great
Britain for the prevention of infection caused by all known
subtypes of hepatitis B virus in adults 18 years of age and older,
and CpG 1018® adjuvant, currently used in multiple
adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018
adjuvant as a premier vaccine adjuvant with adjuvanted vaccine
clinical programs for shingles and Tdap, and through global
collaborations, currently focused on adjuvanted vaccines for
COVID-19, plague, seasonal influenza and universal influenza. For
more information about our marketed products and development
pipeline, visit www.dynavax.com and follow Dynavax on
LinkedIn and Twitter.
For Investors/Media:
Paul
Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-4th-annual-hepatitis-b-virus-virtual-conference-301962390.html
SOURCE Dynavax Technologies